Skip to main content

Table 5 Mean changes from study baseline for Mini-AQLQ, ACQ, and nighttime awakenings for the comparisons of CVT-MDI to ALB-HFA, evaluated at 4 weeks

From: Efficacy and safety of ipratropium bromide/albuterol compared with albuterol in patients with moderate-to-severe asthma: a randomized controlled trial

 

ALB-HFA

CVT-MDI

Difference (CVT-MDI – ALB-HFA)

Endpoint

N

Mean

SE

N

Mean

SE

Mean

(95 % CI)

p value

Mini-AQLQ

191

0.15

0.05

193

0.22

0.05

0.06

(−0.03, 0.15)

0.159

ACQ

191

−0.25

0.04

193

−0.25

0.04

0.01

(−0.07, 0.08)

0.828

Nighttime awakenings

178

−0.15

0.02

180

−0.16

0.02

−0.01

(−0.05, 0.04)

0.764

  1. ACQ asthma control questionnaire (7-point scale), ALB-HFA albuterol hydrofluoroalkaline, AQLQ asthma quality of life questionnaire, CVT-MDI ipratropium bromide/albuterol sulfate metered-dose inhaler